OncoLink Editorial Board

Executive Director
James Metz, MD

Editor-in-Chief
Christine Hill-Kayser, MD

Associate Editor
Michell Iocolano, MD

Editor Emeritus 
Neha Vapiwala, MD

Innovation Director
Carolyn Vachani, MSN, RN, AOCN

Web Content Manager
Alexander Rodríguez, MD

Managing Editor
Karen Arnold-Korzeniowski, MSN, RN

Medical Oncology Content Editor
Marisa Healy, BSN, RN

Psychosocial Oncology Content Editor
Christina Bach, MBE, MSW, LCSW, OSW-C

Oncology Content Specialist
Katherine Okonak, LSW
Allyson Van Horn, MPH

Strategic Partnerships Administrator
Courtney Misher, MPH, BS RT(T)

Administrative Coordinator
Viengsammay (Mai) Thammavong

Production Staff
Mike Arrowsmith, Project Manager, Allegiance Group
David Sayre, Technology Lead and Senior Developer, Allegiance Group

Anatomical Illustrator
Meghan Huber Smith, MHS Designs
Jessica Angelini, Biomedical Artist

Contributing Content Specialists
There are many gracious oncology experts who share their time and talents with us. See the list here.

Emeritus Poet-in-Residence
Alysa Cummings

Medical Translator
Evelyn Robles-Rodriguez, DNP, APN, AOCN

Abramson Cancer Center of the University of Pennsylvania Advisors
Robert Vonderheide, MD, Phil Director, Abramson Cancer Center
Lori Gustave, Senior Vice President of Business Development, Penn Medicine
Keith Kasper, CFO, UPHS

Founding Editor
Joel W. Goldwein, MD

OncoLink Editorial Policy
All materials created by OncoLink^® are educational and non-promotional in nature and are prepared, designed, and executed in accordance with the U.S. Food and Drug Administration Guidance on Industry-Supported Scientific and Educational Activities (Policy Statement). The OncoLink^® Editorial Staff creates this content independently and without control or influence by our sponsors. We are committed to educating the public while keeping our content free of commercial bias for or against any product; our sponsors may not require OncoLink^® or the Abramson Cancer Center of the University of Pennsylvania to accept advice or services concerning speakers, authors, participants, or other education matters, including content; OncoLink^® will make meaningful disclosure of each sponsor’s support of the program with banner and text placements as appropriate. Likewise, our licensees will make meaningful disclosure of OncoLink^®’s authorship with banner or text placements as appropriate. The OncoLink^® Editorial Team will ensure that any product discussions in the content will be objective, balanced, and scientifically rigorous. This includes a balanced discussion of the product and of treatment alternatives, limitations on data will be disclosed, and unapproved uses will be identified as such. All funding will be used for educational content creation purposes only.